This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Traductor o intérprete autónomo, Identidad verificada
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Afiliaciones
This person is not affiliated with any business or Blue Board record at ProZ.com.
inglés al español: Bloodless Medicine and Surgery Program General field: Medicina Detailed field: Medicina (general)
Texto de origen - inglés Bloodless Medicine and Surgery Program (BMSP)
Pre-operative Anemia Management
Pre-operative Timing
A. For elective surgeries, a three-to-four week lead time is ideal to initiate hemoglobin optimization.
B. Once a week treatments begin three weeks out from surgery.
C. First dose is given 21 days prior to surgery, 14 days, and 7 days.
This allows optimal time for each regimen to take effect.
D. An additional treatment may be scheduled for the day before surgery, which will provide coverage up to four days post- operatively.
For more urgent surgeries (14 days or less) a more intense optimization regimen is initiated.
In such cases daily treatments up to 10 days before surgery can be initiated.
Classification of Anemia
A. The WHO classification of anemia is based upon gender:
Male Hb < 13.0 g/dl
Female Hb < 12.0 g/dl
B. For surgical patients a more appropriate concept is defining the patient’s hemoglobin as either optimal or suboptimal based upon the complexity of the surgery and degree of blood loss expected.
Regardless of gender, a Hb > 13.0 g/dl should be considered optimal.
Iron Therapy:
Oral vs. Intravenous (IV)
A. Oral iron provides a low-cost treatment for anemia.
Absorption, tolerance, and time are major issues in many patients.
B. IV iron is safe, cost-effective, and more efficient than oral iron.
A visit to the infusion clinic is required and may be inconvenient for certain patients.
C. IV iron allows for rapid replenish of iron stores especially for patients non-responsive to oral iron and those with severe iron deficiency.
D. Dosing is based on total iron deficit (see box below Calculating Iron Deficit).
For some, optimization can be achieved with IV iron alone.
Erythropoietin Stimulating Agents (ESA)
A. In the U.S. rHuEPO use has been approved for patients undergoing elective orthopedic surgery and has been extended for use to other elective, noncardiac, nonvascular surgeries.
B. Off-label use of rHuEPO has been suggested for cardiac or gastrointestinal cancer resection.
Dosing for epoietin alfa has not been standardized.
Two common dosing regimens are 300 IU kg-1 day-1 for daily use and 600 IU kg-1 for weekly use.
Traducción - español Programa de Medicina y Cirugía sin Sangre (PMCS)
Tratamiento de la anemia preoperatoria
Tiempos para el preoperatorio
A. Para cirugías electivas, un período de tres a cuatro semanas previas a la cirugía es ideal para iniciar la optimización de la hemoglobina.
B. Los tratamientos de una vez por semana comienzan tres semanas antes de la cirugía.
C. Se administra la primera dosis a los 21 días anteriores a la cirugía, luego a los 14 días anteriores y luego a los 7 días anteriores.
Esto concede un tiempo óptimo para que cada régimen surta efecto.
D. Es posible que se programe un tratamiento adicional para el día anterior a la cirugía, que proveerá una cobertura de hasta cuatro días en el postoperatorio.
Para cirugías de mayor urgencia (14 días o menos), se inicia un régimen de optimización más intenso.
En estos casos, se pueden iniciar tratamientos diarios hasta 10 días antes de la cirugía.
Clasificación de la anemia
A. La clasificación que brinda la OMS de la anemia se basa en el género:
Masculino Hb < 13,0 g/dl
Femenino Hb < 12,0 g/dl
B. Para los pacientes quirúrgicos, un concepto más apropiado es definir si la hemoglobina del paciente es óptima o inferior al nivel óptimo en base a la complejidad de la cirugía y el nivel de pérdida de sangre estipulado.
Independientemente del género, Hb > 13,0 g/dl se considera óptimo.
Terapia de hierro:
Oral versus intravenoso (IV)
A. El hierro por vía oral constituye un tratamiento de bajo costo para la anemia.
La absorción, la tolerancia y el tiempo son problemas serios para muchos pacientes.
B. El hierro intravenoso es seguro, económico y más eficiente que el hierro por vía oral.
Es necesario realizar una visita a un centro de infusiones y puede ser inconveniente para ciertos pacientes.
C. El hierro intravenoso permite una reposición rápida de los depósitos de hierro, especialmente en el caso de pacientes que no responden al hierro por vía oral y aquellos con deficiencia de hierro grave.
D. La dosificación se basa en un déficit total de hierro (ver cuadro a continuación, Calculando el Déficit de Hierro)
En algunos casos, la optimización se puede alcanzar solamente con hierro intravenoso.
Agente estimulador de la eritropoyetina (ESA)
A. En los Estados Unidos, la rHuEPO ha sido aprobada para pacientes sometidos a una cirugía ortopédica electiva y su uso se ha extendido a otras cirugías electivas, no cardíacas y no vasculares.
B. El uso fuera de indicación de la rHuEPO ha sido sugerido para la resección cardíaca o de cáncer gastrointestinal.
La dosificación de la epoetina alfa no ha sido normalizada.
Dos regímenes comunes de dosificación son 300 UI kg-1 día-1 para uso diario y 600 UI kg-1 para uso semanal.
More
Less
Formación en el ámbito de la traducción
Graduate diploma - Universidad Nacional de Córdoba
Experiencia
Años de experiencia: 5 Registrado en ProZ.com: Feb 2014
español al inglés (Cambridge University (ESOL Examinations)) inglés al español (Cambridge University (ESOL Examinations)) español al inglés (Universidad Nacional de Córdoba (Facultad de Lenguas), verified) inglés al español (Universidad Nacional de Córdoba (Facultad de Lenguas), verified)
Miembro de
N/A
Software
Adobe Acrobat, MateCat, memoQ, Microsoft Word, OmegaT, Trados Studio, Wordfast
Get help on technical issues / improve my technical skills
Learn more about additional services I can provide my clients
Meet new end/direct clients
Work for non-profits or pro-bono clients
Network with other language professionals
Find trusted individuals to outsource work to
Get help with terminology and resources
Learn more about translation / improve my skills
Learn more about interpreting / improve my skills
Learn more about the business side of freelancing
Stay up to date on what is happening in the language industry
Help or teach others with what I have learned over the years
Buy or learn new work-related software
Improve my productivity
Bio
I graduated from the National University of Córdoba, Argentina in 2014. I have six years of professional translation experience working with translation agencies from Argentina, the U.S., and Europe, as well as with independent clients. In my previous collaborations, I have worked within a wide range of translation fields including technical, marketing, and literary translation, but mostly with medical projects.
In the past few years, I have leaned into a specialization in medicine and life sciences, by pursuing field-specific translation projects and taking several courses on medicine, clinical trials, pharmacology, and biology. I am currently enrolled in a Masters's Course for Medical Translation.
I have also gained first-hand experience in the field of clinical trials by working for the past year and a half as a bilingual patient engagement associate for a neurology clinical research site. My tasks included providing over-the-phone and video interpreting and translation of patient-facing materials for Spanish-speaking patients throughout pre-screening, screening, randomization, and clinic visits.